董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard DiMarchi | 男 | Director | 69 | 9.76万美元 | 未持股 | 2022-03-28 |
| Gina Consylman | 女 | Director | 50 | 9.76万美元 | 未持股 | 2022-03-28 |
| John G. McHutchison | 男 | Director, Chief Executive Officer and President | 64 | 286.58万美元 | 未持股 | 2022-03-28 |
| Susan Mahony | 女 | Director | 57 | 10.20万美元 | 未持股 | 2022-03-28 |
| Michael Houghton | 男 | Director | 71 | 10.30万美元 | 未持股 | 2022-03-28 |
| Lisa R. Johnson Pratt | 女 | Director | 58 | 12.34万美元 | 未持股 | 2022-03-28 |
| Anthony E. Altig | 男 | Director | 66 | 11.26万美元 | 未持股 | 2022-03-28 |
| William Ringo | 男 | Director | 76 | 15.51万美元 | 未持股 | 2022-03-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John G. McHutchison | 男 | Director, Chief Executive Officer and President | 64 | 286.58万美元 | 未持股 | 2022-03-28 |
| Jason A. Okazaki | 男 | Chief Operating Officer | 46 | 127.82万美元 | 未持股 | 2022-03-28 |
| William E. Delaney IV | 男 | Chief Scientific Officer | 50 | 101.81万美元 | 未持股 | 2022-03-28 |
| Luisa M. Stamm | 女 | Chief Medical Officer | 46 | 未披露 | 未持股 | 2022-03-28 |
| Michael P. Samar | 男 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2022-03-28 |
董事简历
中英对照 | 中文 | 英文- Richard DiMarchi
-
Richard DiMarchi在2014年7月（Assembly收购的关闭）成为董事。DiMarchi博士是Assembly Pharmaceuticals的联合创始人，自2012年成立以来服务于其董事会。DiMarchi博士目前持有考克斯生物化学特聘教授（Cox Distinguished Professor of Biochemistry）和Indiana University生物分子科学吉尔主席职位。DiMarchi博士是生物技术公司Ambrx和Marcadia的联合创始人和董事会成员，Assembly and Calibrium Biotech的当前创始人，风险公司5AM, Twilight Ventures和其他公司的顾问。DiMarchi博士从Eli Lilly & Company退休（担任集团副总裁），在那里他领导生物技术，内分泌研究和产品开发20多年。DiMarchi博士此前担任生物科技贸易集团BIO, Isis and Millennium BioTherapeutics的董事会成员。他目前的研究重点是通过生物化学和化学优化发展增强治疗属性的高分子（一个他称为化学生物技术的方法）。DiMarchi博士为Humalog的发现以及Humulin, Humatrope, Glucagon, Xigris, Forteo和Evista的商业开发做出了重要贡献。DiMarchi博士获得许多著名的奖项，于2014年被引入全国发明家名人堂（the National Inventors Hall of Fame）。DiMarchi博士获得Indiana University生物化学博士学位，在Rockefeller University完成他的博士后学习。
Richard DiMarchi joined our Board in July 2014 upon the closing of the Merger. Dr. DiMarchi was a co-founder of Assembly Pharmaceuticals, Inc. and served on its board from its inception in 2012 through the Merger. Dr. DiMarchi is a Distinguished Professor of Chemical Biology and Gill Chair in Biomolecular Sciences at Indiana University and Chief Scientific Officer of MBX Biosciences, Inc. From February 2016 until March 2020 Dr. DiMarchi served as Vice President of Research at Novo Nordisk Research Labs. Dr. DiMarchi was a co-founder and board member of biotechnology companies Ambrx, Inc. until it was acquired by a consortium of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund and WuXi PharmaTech and Marcadia Biotech Inc. (until it was acquired by Roche in 2010). Dr. DiMarchi was also a founder of Calibrium LLC, which was acquired by Novo Nordisk in 2015 and an advisor to Twilight Ventures. Dr. DiMarchi retired as Group Vice President at Eli Lilly & Company (Lilly), where he provided leadership for more than two decades in biotechnology, endocrine research, and product development. Dr. DiMarchi previously served as a board member of the biotechnology trade group BIO, Ionis Pharmaceuticals, Inc. (f/k/a Isis Pharmaceuticals, Inc.) and Millennium BioTherapeutics, Inc. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization. Dr. DiMarchi contributed significantly to the discovery of Humalog® and to the commercial development of pharmaceutical products Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo®, and Evista®. Dr. DiMarchi is the recipient of numerous prestigious awards and in 2014 was inducted to the National Inventors Hall of Fame and in 2015 to the National Academy of Medicine. Dr. DiMarchi received a B.S. with honors from Florida Atlantic University and his Ph.D. in Biochemistry from Indiana University and completed his postdoctoral studies at the Rockefeller University. - Richard DiMarchi在2014年7月（Assembly收购的关闭）成为董事。DiMarchi博士是Assembly Pharmaceuticals的联合创始人，自2012年成立以来服务于其董事会。DiMarchi博士目前持有考克斯生物化学特聘教授（Cox Distinguished Professor of Biochemistry）和Indiana University生物分子科学吉尔主席职位。DiMarchi博士是生物技术公司Ambrx和Marcadia的联合创始人和董事会成员，Assembly and Calibrium Biotech的当前创始人，风险公司5AM, Twilight Ventures和其他公司的顾问。DiMarchi博士从Eli Lilly & Company退休（担任集团副总裁），在那里他领导生物技术，内分泌研究和产品开发20多年。DiMarchi博士此前担任生物科技贸易集团BIO, Isis and Millennium BioTherapeutics的董事会成员。他目前的研究重点是通过生物化学和化学优化发展增强治疗属性的高分子（一个他称为化学生物技术的方法）。DiMarchi博士为Humalog的发现以及Humulin, Humatrope, Glucagon, Xigris, Forteo和Evista的商业开发做出了重要贡献。DiMarchi博士获得许多著名的奖项，于2014年被引入全国发明家名人堂（the National Inventors Hall of Fame）。DiMarchi博士获得Indiana University生物化学博士学位，在Rockefeller University完成他的博士后学习。
- Richard DiMarchi joined our Board in July 2014 upon the closing of the Merger. Dr. DiMarchi was a co-founder of Assembly Pharmaceuticals, Inc. and served on its board from its inception in 2012 through the Merger. Dr. DiMarchi is a Distinguished Professor of Chemical Biology and Gill Chair in Biomolecular Sciences at Indiana University and Chief Scientific Officer of MBX Biosciences, Inc. From February 2016 until March 2020 Dr. DiMarchi served as Vice President of Research at Novo Nordisk Research Labs. Dr. DiMarchi was a co-founder and board member of biotechnology companies Ambrx, Inc. until it was acquired by a consortium of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund and WuXi PharmaTech and Marcadia Biotech Inc. (until it was acquired by Roche in 2010). Dr. DiMarchi was also a founder of Calibrium LLC, which was acquired by Novo Nordisk in 2015 and an advisor to Twilight Ventures. Dr. DiMarchi retired as Group Vice President at Eli Lilly & Company (Lilly), where he provided leadership for more than two decades in biotechnology, endocrine research, and product development. Dr. DiMarchi previously served as a board member of the biotechnology trade group BIO, Ionis Pharmaceuticals, Inc. (f/k/a Isis Pharmaceuticals, Inc.) and Millennium BioTherapeutics, Inc. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization. Dr. DiMarchi contributed significantly to the discovery of Humalog® and to the commercial development of pharmaceutical products Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo®, and Evista®. Dr. DiMarchi is the recipient of numerous prestigious awards and in 2014 was inducted to the National Inventors Hall of Fame and in 2015 to the National Academy of Medicine. Dr. DiMarchi received a B.S. with honors from Florida Atlantic University and his Ph.D. in Biochemistry from Indiana University and completed his postdoctoral studies at the Rockefeller University.
- Gina Consylman
-
Gina Consylman自2017年11月以来一直担任我们的高级副总裁，首席财务官。Consylman女士曾于2017年9月至2017年11月担任我们的临时首席财务官，并于2015年8月至2017年11月担任我们的财务Vice President兼首席会计官。她此前曾于2014年6月至2015年7月担任我们的Vice President、公司财务总监和首席会计官。在加入Ironwood之前，Consylman女士曾担任Analogic Corporation（Analogic）的Vice President、公司财务总监兼首席会计官，2012年2月至2014年6月，Analogic被Altaris Capital Partners，LLC的附属基金收购，她在该公司监管Analogic的全球会计团队，在加入Analogic之前，Consylman从2009年11月到2012年2月在BiogenInc.（Biogen）担任多个财务职位，最终担任公司会计高级主管，在加入Biogen之前，她负责公司和美国商业业务部门的会计团队，Consylman女士还曾担任Varian Semiconductor Equipment Associates，Inc.（后被应用材料公司收购）的公司财务总监。Consylman女士目前在Verastem，Inc.董事会任职，包括担任审计委员会主席Consylman女士是一名注册会计师，在Ernst&Young LLP开始了她的公共会计职业生涯。她持有Johnson&Wales University的会计学士学位，以及Bentley University的税务硕士学位。
Gina Consylman joined our Board in October 2020. Since April 2022 Ms. Consylman has served as Chief Financial Officer of Vedere Bio II, Inc. Prior to that, Ms. Consylman served as Chief Financial Officer of bluebird bio, Inc bluebird bio from November 2021 until April 2022. Prior her service as Chief Financial Officer of bluebird bio, Ms. Consylman served as the Chief Financial Officer of bluebird bio’s Severe Genetic Disease business. Prior to joining bluebird bio, from November 2017 until July 2021 Ms. Consylman served as Senior Vice President, Chief Financial Officer of Ironwood Pharmaceuticals, Inc. (Ironwood). From September 2017 until November 2017 Ms. Consylman was Ironwood’s interim Chief Financial Officer, from August 2015 until November 2017 she served as Ironwood’s Vice President of Finance and Chief Accounting Officer and from June 2014 until July 2015 she served as Ironwood’s Vice President, Corporate Controller and Chief Accounting Officer. Prior to joining Ironwood, Ms. Consylman served as Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation from February 2012 until June 2014. Prior to that, Ms. Consylman served in various roles of increasing responsibility at Biogen Inc. from November 2009 until February 2012 culminating in her role as Senior Director, Corporate Accounting. Prior to that, Ms. Consylman served as Corporate Controller at Varian Semiconductor Equipment Associates, Inc. From October 2018 until November 2021 Ms. Consylman served on the board of directors and as chair of the audit committee of Verastem, Inc., a public company. Ms. Consylman received her B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University. Ms. Consylman is a Certified Public Accountant. - Gina Consylman自2017年11月以来一直担任我们的高级副总裁，首席财务官。Consylman女士曾于2017年9月至2017年11月担任我们的临时首席财务官，并于2015年8月至2017年11月担任我们的财务Vice President兼首席会计官。她此前曾于2014年6月至2015年7月担任我们的Vice President、公司财务总监和首席会计官。在加入Ironwood之前，Consylman女士曾担任Analogic Corporation（Analogic）的Vice President、公司财务总监兼首席会计官，2012年2月至2014年6月，Analogic被Altaris Capital Partners，LLC的附属基金收购，她在该公司监管Analogic的全球会计团队，在加入Analogic之前，Consylman从2009年11月到2012年2月在BiogenInc.（Biogen）担任多个财务职位，最终担任公司会计高级主管，在加入Biogen之前，她负责公司和美国商业业务部门的会计团队，Consylman女士还曾担任Varian Semiconductor Equipment Associates，Inc.（后被应用材料公司收购）的公司财务总监。Consylman女士目前在Verastem，Inc.董事会任职，包括担任审计委员会主席Consylman女士是一名注册会计师，在Ernst&Young LLP开始了她的公共会计职业生涯。她持有Johnson&Wales University的会计学士学位，以及Bentley University的税务硕士学位。
- Gina Consylman joined our Board in October 2020. Since April 2022 Ms. Consylman has served as Chief Financial Officer of Vedere Bio II, Inc. Prior to that, Ms. Consylman served as Chief Financial Officer of bluebird bio, Inc bluebird bio from November 2021 until April 2022. Prior her service as Chief Financial Officer of bluebird bio, Ms. Consylman served as the Chief Financial Officer of bluebird bio’s Severe Genetic Disease business. Prior to joining bluebird bio, from November 2017 until July 2021 Ms. Consylman served as Senior Vice President, Chief Financial Officer of Ironwood Pharmaceuticals, Inc. (Ironwood). From September 2017 until November 2017 Ms. Consylman was Ironwood’s interim Chief Financial Officer, from August 2015 until November 2017 she served as Ironwood’s Vice President of Finance and Chief Accounting Officer and from June 2014 until July 2015 she served as Ironwood’s Vice President, Corporate Controller and Chief Accounting Officer. Prior to joining Ironwood, Ms. Consylman served as Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation from February 2012 until June 2014. Prior to that, Ms. Consylman served in various roles of increasing responsibility at Biogen Inc. from November 2009 until February 2012 culminating in her role as Senior Director, Corporate Accounting. Prior to that, Ms. Consylman served as Corporate Controller at Varian Semiconductor Equipment Associates, Inc. From October 2018 until November 2021 Ms. Consylman served on the board of directors and as chair of the audit committee of Verastem, Inc., a public company. Ms. Consylman received her B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University. Ms. Consylman is a Certified Public Accountant.
- John G. McHutchison
-
John G. McHutchison于2018年3月被任命为首席科学官。在加入Gilead之前，McHutchison博士曾在杜克大学医学中心工作，并担任过杜克临床研究所副所长。 他还担任过杜克大学医学中心胃肠病学系医学教授，杜克大学临床研究所副所长和杜克大学临床与转化科学奖的联合主任。 在Duke任职之前，McHutchison博士在Scripps诊所工作了近10年，最近担任肝脏移植医学总监。 他之前还曾在南加州大学担任医学助理教授。
John G. McHutchison has served as our Chief Executive Officer and President and as a director since August 2019. Prior to joining us, Dr. McHutchison was the Chief Scientific Officer and Head of Research and Development at Gilead Sciences, Inc. Gilead. Prior to joining Gilead in 2010 Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke University, Dr. McHutchison spent nearly ten years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018 Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology. Dr. McHutchison has undergraduate degrees in medicine and surgery from the University of Melbourne in Australia and completed his residency in internal medicine and fellowship in gastroenterology at the Royal Melbourne Hospital. He is a member of the Royal Australasian College of Physicians. Dr. McHutchison currently serves on the board of directors of Metacrine, Inc., a public company, and Evox Therapeutics and Oxford BioTherapeutics, both private companies. - John G. McHutchison于2018年3月被任命为首席科学官。在加入Gilead之前，McHutchison博士曾在杜克大学医学中心工作，并担任过杜克临床研究所副所长。 他还担任过杜克大学医学中心胃肠病学系医学教授，杜克大学临床研究所副所长和杜克大学临床与转化科学奖的联合主任。 在Duke任职之前，McHutchison博士在Scripps诊所工作了近10年，最近担任肝脏移植医学总监。 他之前还曾在南加州大学担任医学助理教授。
- John G. McHutchison has served as our Chief Executive Officer and President and as a director since August 2019. Prior to joining us, Dr. McHutchison was the Chief Scientific Officer and Head of Research and Development at Gilead Sciences, Inc. Gilead. Prior to joining Gilead in 2010 Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke University, Dr. McHutchison spent nearly ten years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018 Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology. Dr. McHutchison has undergraduate degrees in medicine and surgery from the University of Melbourne in Australia and completed his residency in internal medicine and fellowship in gastroenterology at the Royal Melbourne Hospital. He is a member of the Royal Australasian College of Physicians. Dr. McHutchison currently serves on the board of directors of Metacrine, Inc., a public company, and Evox Therapeutics and Oxford BioTherapeutics, both private companies.
- Susan Mahony
-
Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
Susan Mahony has served as a member of Board of Directors since June 2019 and as Lead Independent Director of Board of Directors since December 2023. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until Augt 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resces, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering Plough, Amgen, and Bristol Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors of Axsome Therapeutics, Inc. since October 2023, and on the board of directors of Catalent, Inc. since February 2025. She previoly served on the board of directors of Horizon Therapeutics Public Limited Company from Augt 2019 to October 2023 (acquired by Amgen Inc.) and on the board of directors of Vifor Pharma from May 2019 until Augt 2022 (acquired by CSL Limited). Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Biness School. Dr. Mahony is NACD Directorship Certified[]. - Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
- Susan Mahony has served as a member of Board of Directors since June 2019 and as Lead Independent Director of Board of Directors since December 2023. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until Augt 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resces, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering Plough, Amgen, and Bristol Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017, on the board of directors of Axsome Therapeutics, Inc. since October 2023, and on the board of directors of Catalent, Inc. since February 2025. She previoly served on the board of directors of Horizon Therapeutics Public Limited Company from Augt 2019 to October 2023 (acquired by Amgen Inc.) and on the board of directors of Vifor Pharma from May 2019 until Augt 2022 (acquired by CSL Limited). Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Biness School. Dr. Mahony is NACD Directorship Certified[].
- Michael Houghton
-
Michael Houghton于2021年7月加入我们的董事会。自2010年以来，Houghton博士一直担任艾伯塔大学医学微生物学和免疫学系的La Ka Shing教授。霍顿博士也是李嘉诚应用病毒研究所的主任。2020年，霍顿博士与哈维·J·奥特和查尔斯·赖斯共同被评为2020年诺贝尔生理学或医学奖获得者，以表彰丙型肝炎病毒HCV的发现。2010年至2018年期间，霍顿博士还担任加拿大艾伯塔大学病毒学卓越研究主席。在加入艾伯塔大学之前，霍顿博士在2007年至2009年期间担任Epiphany Biosciences，Inc.的首席科学官。在加入Epiphany之前，Houghton博士曾在诺华疫苗和诊断公司（诺华）担任丙型肝炎和病毒学研究副总裁。在此之前，Houghton博士从1982年到2006年在Chiron公司担任了多个职位，职责不断增加。Houghton博士在Prophysis公司、Aurora Vaccines公司、Achlys公司、Heka治疗公司和Egerio公司的董事会任职，这些公司都是加拿大的私营初创公司。霍顿博士在东英吉利大学获得生物科学学士学位，在伦敦大学国王学院获得生物化学博士学位，并被东英吉利大学授予荣誉科学博士学位。
Michael Houghton joined our Board in July 2021. Since 2010 Dr. Houghton has served as the La Ka Shing Professor in the Department of Medical Microbiology and Immunology at the University of Alberta. Dr. Houghton is also the director of the La Ka Shing Applied Virology Institute. In 2020 Dr. Houghton was jointly named the 2020 Nobel Prize winner in Physiology or Medicine along with Harvey J. Alter and Charles M. Rice in recognition of the discovery of hepatitis C virus HCV. Between 2010 and 2018 Dr. Houghton was also the Canada Excellence Research Chair in Virology at the University of Alberta. Prior to joining the University of Alberta, Dr. Houghton served as Chief Scientific Officer at Epiphany Biosciences, Inc. (Epiphany) from 2007 until 2009. Before joining Epiphany, Dr. Houghton served as Vice President, Hepatitis C and Virology Research at Novartis Vaccines & Diagnostics, Inc. (Novartis). Prior to that, Dr. Houghton served in a number of positions of increasing responsibility at Chiron Corporation (Chiron) from 1982 until 2006. Dr. Houghton serves on the boards of directors of Prophysis Inc., Aurora Vaccines Inc, Achlys Inc., Heka Therapeutics Inc. and Egerio Inc., all private Canadian startup companies. Dr. Houghton received his B.Sc. in Biological Sciences from the University of East Anglia and his Ph.D. in Biochemistry from King’s College at the University of London and was awarded an Honorary Doctorate of Sciences from the University of East Anglia. - Michael Houghton于2021年7月加入我们的董事会。自2010年以来，Houghton博士一直担任艾伯塔大学医学微生物学和免疫学系的La Ka Shing教授。霍顿博士也是李嘉诚应用病毒研究所的主任。2020年，霍顿博士与哈维·J·奥特和查尔斯·赖斯共同被评为2020年诺贝尔生理学或医学奖获得者，以表彰丙型肝炎病毒HCV的发现。2010年至2018年期间，霍顿博士还担任加拿大艾伯塔大学病毒学卓越研究主席。在加入艾伯塔大学之前，霍顿博士在2007年至2009年期间担任Epiphany Biosciences，Inc.的首席科学官。在加入Epiphany之前，Houghton博士曾在诺华疫苗和诊断公司（诺华）担任丙型肝炎和病毒学研究副总裁。在此之前，Houghton博士从1982年到2006年在Chiron公司担任了多个职位，职责不断增加。Houghton博士在Prophysis公司、Aurora Vaccines公司、Achlys公司、Heka治疗公司和Egerio公司的董事会任职，这些公司都是加拿大的私营初创公司。霍顿博士在东英吉利大学获得生物科学学士学位，在伦敦大学国王学院获得生物化学博士学位，并被东英吉利大学授予荣誉科学博士学位。
- Michael Houghton joined our Board in July 2021. Since 2010 Dr. Houghton has served as the La Ka Shing Professor in the Department of Medical Microbiology and Immunology at the University of Alberta. Dr. Houghton is also the director of the La Ka Shing Applied Virology Institute. In 2020 Dr. Houghton was jointly named the 2020 Nobel Prize winner in Physiology or Medicine along with Harvey J. Alter and Charles M. Rice in recognition of the discovery of hepatitis C virus HCV. Between 2010 and 2018 Dr. Houghton was also the Canada Excellence Research Chair in Virology at the University of Alberta. Prior to joining the University of Alberta, Dr. Houghton served as Chief Scientific Officer at Epiphany Biosciences, Inc. (Epiphany) from 2007 until 2009. Before joining Epiphany, Dr. Houghton served as Vice President, Hepatitis C and Virology Research at Novartis Vaccines & Diagnostics, Inc. (Novartis). Prior to that, Dr. Houghton served in a number of positions of increasing responsibility at Chiron Corporation (Chiron) from 1982 until 2006. Dr. Houghton serves on the boards of directors of Prophysis Inc., Aurora Vaccines Inc, Achlys Inc., Heka Therapeutics Inc. and Egerio Inc., all private Canadian startup companies. Dr. Houghton received his B.Sc. in Biological Sciences from the University of East Anglia and his Ph.D. in Biochemistry from King’s College at the University of London and was awarded an Honorary Doctorate of Sciences from the University of East Anglia.
- Lisa R. Johnson Pratt
-
Lisa R. Johnson Pratt于2021年5月当选为董事会成员。自2020年11月以来，Johnson-Pratt博士一直担任副总裁，负责商业0Ionis.在此之前，Johnson-Pratt博士从2020年3月起担任Akcea治疗公司的高级副总裁，直到Ionis收购Akcea，该收购于2020年10月完成。在此之前，Johnson-Pratt博士于2018年1月至2019年7月担任副总裁0全球特许经营业务副总裁，并于2015年6月至2019年7月担任GSK管道和肿瘤商业战略主管。从2013年到2015年，Johnson-Pratt博士担任Stiefel Laboratories，Inc.的全球营销总监。Johnson-Pratt博士从2004年到2013年在默克公司工作，担任过一系列越来越重要的职务，最终担任业务部总监（成熟品牌）。Johnson-Pratt博士是Tracon制药公司（一家上市公司）的董事会成员。Johnson-Pratt博士在霍华德大学获得科学学士学位，在皇家内科医学院获得药物医学文凭，在霍华德大学获得医学博士学位。
Lisa R. Johnson Pratt was elected to our Board in May 2021. Since November 2020 Dr. Johnson-Pratt has served as Senior Vice President, Commercial of Ionis Pharmaceuticals, Inc. Ionis. Prior to that, Dr. Johnson-Pratt served as Senior Vice President of Akcea Therapeutics, Inc. (Akcea) from March 2020 until Ionis’s acquisition of Akcea, which was consummated in October 2020. Prior to that, Dr. Johnson-Pratt served as Vice President of Global Franchise Operations at GlaxoSmithKline plc (GSK) from January 2018 until July 2019 and from June 2015 until July 2019 she served as GSK’s Head, Pipeline and Oncology Commercial Strategy. From 2013 until 2015 Dr. Johnson-Pratt was the Global Marketing Director at Stiefel Laboratories, Inc. Dr. Johnson-Pratt worked for Merck & Co., Inc. from 2004 until 2013 in a series of positions of increasing responsibility, culminating in her role as Business Unit Director (Mature Brands). Dr. Johnson-Pratt serves on the board of directors of Tracon Pharmaceuticals, Inc., a public company. Dr. Johnson-Pratt earned a B.S. in science from Howard University, a Diploma of Pharmaceutical Medicine from the Royal College of Physicians, and an M.D. from Howard University. - Lisa R. Johnson Pratt于2021年5月当选为董事会成员。自2020年11月以来，Johnson-Pratt博士一直担任副总裁，负责商业0Ionis.在此之前，Johnson-Pratt博士从2020年3月起担任Akcea治疗公司的高级副总裁，直到Ionis收购Akcea，该收购于2020年10月完成。在此之前，Johnson-Pratt博士于2018年1月至2019年7月担任副总裁0全球特许经营业务副总裁，并于2015年6月至2019年7月担任GSK管道和肿瘤商业战略主管。从2013年到2015年，Johnson-Pratt博士担任Stiefel Laboratories，Inc.的全球营销总监。Johnson-Pratt博士从2004年到2013年在默克公司工作，担任过一系列越来越重要的职务，最终担任业务部总监（成熟品牌）。Johnson-Pratt博士是Tracon制药公司（一家上市公司）的董事会成员。Johnson-Pratt博士在霍华德大学获得科学学士学位，在皇家内科医学院获得药物医学文凭，在霍华德大学获得医学博士学位。
- Lisa R. Johnson Pratt was elected to our Board in May 2021. Since November 2020 Dr. Johnson-Pratt has served as Senior Vice President, Commercial of Ionis Pharmaceuticals, Inc. Ionis. Prior to that, Dr. Johnson-Pratt served as Senior Vice President of Akcea Therapeutics, Inc. (Akcea) from March 2020 until Ionis’s acquisition of Akcea, which was consummated in October 2020. Prior to that, Dr. Johnson-Pratt served as Vice President of Global Franchise Operations at GlaxoSmithKline plc (GSK) from January 2018 until July 2019 and from June 2015 until July 2019 she served as GSK’s Head, Pipeline and Oncology Commercial Strategy. From 2013 until 2015 Dr. Johnson-Pratt was the Global Marketing Director at Stiefel Laboratories, Inc. Dr. Johnson-Pratt worked for Merck & Co., Inc. from 2004 until 2013 in a series of positions of increasing responsibility, culminating in her role as Business Unit Director (Mature Brands). Dr. Johnson-Pratt serves on the board of directors of Tracon Pharmaceuticals, Inc., a public company. Dr. Johnson-Pratt earned a B.S. in science from Howard University, a Diploma of Pharmaceutical Medicine from the Royal College of Physicians, and an M.D. from Howard University.
- Anthony E. Altig
-
Anthony E. Altig，2012年，他加入我公司董事会。2008年起，他担任Biotix Holdings, Inc.的首席财务官，该公司制造微生物消耗品。2004至2007年，他担任Diversa Corporation（即后来的Verenium Corporation）的首席财务官，该公司是上市公司，开发专门工业酶。加入Diversa之前，他担任上市生物制药公司Maxim Pharmaceuticals, Inc.的首席财务官。此外，他还是TearLab Corporation （前身为OccuLogix, Inc.）的董事和审计委员会主席， 该公司是上市眼部护理技术公司，并担任上市制药公司Optimer Pharmaceuticals, Inc.的董事，随后被Cubist Pharmaceuticals, Inc.收购。
Anthony E. Altig joined our Board in January 2012. From 2008 until his retirement in December 2017 Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007 Mr. Altig served as the Chief Financial Officer of Diversa Corporation subsequently Verenium Corporation, a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. Mr. Altig formerly served as a director and chairman of the audit committee of TearLab Corporation (formerly OccuLogix, Inc.), an eyecare technology company that was a public company until it was taken private in July 2020 and as a director of MultiCell Technologies, Inc. and Optimer Pharmaceuticals, Inc., a pharmaceutical company that was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. Mr. Altig received his B.B.A. in business from the University of Hawaii at Manoa and is a Certified Public Accountant (inactive). - Anthony E. Altig，2012年，他加入我公司董事会。2008年起，他担任Biotix Holdings, Inc.的首席财务官，该公司制造微生物消耗品。2004至2007年，他担任Diversa Corporation（即后来的Verenium Corporation）的首席财务官，该公司是上市公司，开发专门工业酶。加入Diversa之前，他担任上市生物制药公司Maxim Pharmaceuticals, Inc.的首席财务官。此外，他还是TearLab Corporation （前身为OccuLogix, Inc.）的董事和审计委员会主席， 该公司是上市眼部护理技术公司，并担任上市制药公司Optimer Pharmaceuticals, Inc.的董事，随后被Cubist Pharmaceuticals, Inc.收购。
- Anthony E. Altig joined our Board in January 2012. From 2008 until his retirement in December 2017 Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007 Mr. Altig served as the Chief Financial Officer of Diversa Corporation subsequently Verenium Corporation, a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. Mr. Altig formerly served as a director and chairman of the audit committee of TearLab Corporation (formerly OccuLogix, Inc.), an eyecare technology company that was a public company until it was taken private in July 2020 and as a director of MultiCell Technologies, Inc. and Optimer Pharmaceuticals, Inc., a pharmaceutical company that was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. Mr. Altig received his B.B.A. in business from the University of Hawaii at Manoa and is a Certified Public Accountant (inactive).
- William Ringo
-
William Ringo，2014年2月以来，他担任沃恩董事会成员。分别从2010年6月和2010年6月以来，他担任Barclays Healthcare Group高级顾问和的Sofinnova Ventures的战略顾问。从2008年4月到2010年4月退休，他担任Pfizer Inc.（上市医药公司）业务发展，战略和创新高级副总裁，负责领导Pfizer的总体战略规划和业务发展的活动。加入Pfizer之前，他担任总体战略规划和业务发展的活动的住校执行官。从2004年8月到2006年4月，他曾担任Abgenix,Inc.（生物技术公司，专注于发展人类抗体作为媒介治疗癌症和其他严重的疾病）的总裁和首席执行官。他的事业始于1973年在Eli Lilly & Company任职，在任职的28年期间，他担任许多高级职务，包括肿瘤学和急救护理产品部门总裁，传染病业务单元总裁和美国制药的销售和营销副总裁。他与2001年1月从 Lilly退休。从2001年3月到2007年12月，他曾在不同的董事会董事职务，包括Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc.和InterMune, Inc.。从2003年6月到2003年9月担任临时执行副总裁之后，他担任非执行主席。他也在BioCrossroads（公私合作的企业、大学、政府和企业领导商，支持印第安纳州的生命科学研究和生命科学公司，并促进该区域的业务发展）的董事会任职。他获得印第安纳州的生命科学研究和生命科学公司的工商管理学士学位和工商管理硕士学位。
William Ringo became a director in July 2014 upon the closing of the Assembly Pharmaceuticals, Inc. acquisition through a reverse merger by Assembly Biosciences, Inc. predecessor company, Ventrus Biosciences, Inc. the Merger and became non-executive Chairman of the Board in February 2015. Mr. Ringo served as Interim Chief Executive Officer of Five Prime Therapeutics, Inc. (Five Prime) from September 2019 until April 2020. From July 2010 until December 2015 Mr. Ringo was a senior advisor with Barclays Capital, the global investment banking division of Barclays Bank PLC. From July 2010 until December 2015 Mr. Ringo served as a strategic advisor with Sofinnova Ventures, a life sciences-focused investment firm. Prior to his advisory roles with Barclays Capital and Sofinnova Ventures, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer Inc., a biopharmaceutical company, from April 2008 until his retirement in April 2010. From 2004 to 2006 Mr. Ringo served as President and Chief Executive Officer of Abgenix, Inc., a biotechnology company acquired by Amgen, Inc. From 2001 to 2007 he served on various boards of directors, including the following public companies: Encysive Pharmaceuticals, Inc.; Inspire Pharmaceuticals, Inc.; and InterMune, Inc., where he was the non-executive chairman of the board of directors after serving as interim Chief Executive Officer from June 2003 to September 2003. His experience in the global pharmaceutical sector also includes nearly 30 years with Lilly. Over the course of his career with Lilly, Mr. Ringo served in numerous executive roles, including Product Group President for oncology and critical care, President of internal medicine products, President of the infectious diseases business unit, and Vice President of sales and marketing for U.S. pharmaceuticals. He also was a member of Lilly's operating committee. From 1994 to 2002 he served as a director and chairman of the board for Community Health Systems, Inc. and from February 2011 until the October 2013 acquisition by Amgen, Inc., on the Onyx Pharmaceuticals, Inc. board of directors. In the last five years, Mr. Ringo served as a director of Immune Design Corp., Sangamo Biosciences, Inc., Mirati Technologies, Inc., each public companies, and Dermira, Inc. (Dermira) prior to Dermira being acquired by Lilly and Five Prime prior to Five Prime being acquired by Amgen Inc. Prior to being acquired, both Dermira and Five Prime were also public companies. In addition, Mr. Ringo currently serves as the chairman of the board at Sensei Biotherapeutics, Inc. Mr. Ringo received a B.S. in business administration and an M.B.A. from the University of Dayton. - William Ringo，2014年2月以来，他担任沃恩董事会成员。分别从2010年6月和2010年6月以来，他担任Barclays Healthcare Group高级顾问和的Sofinnova Ventures的战略顾问。从2008年4月到2010年4月退休，他担任Pfizer Inc.（上市医药公司）业务发展，战略和创新高级副总裁，负责领导Pfizer的总体战略规划和业务发展的活动。加入Pfizer之前，他担任总体战略规划和业务发展的活动的住校执行官。从2004年8月到2006年4月，他曾担任Abgenix,Inc.（生物技术公司，专注于发展人类抗体作为媒介治疗癌症和其他严重的疾病）的总裁和首席执行官。他的事业始于1973年在Eli Lilly & Company任职，在任职的28年期间，他担任许多高级职务，包括肿瘤学和急救护理产品部门总裁，传染病业务单元总裁和美国制药的销售和营销副总裁。他与2001年1月从 Lilly退休。从2001年3月到2007年12月，他曾在不同的董事会董事职务，包括Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc.和InterMune, Inc.。从2003年6月到2003年9月担任临时执行副总裁之后，他担任非执行主席。他也在BioCrossroads（公私合作的企业、大学、政府和企业领导商，支持印第安纳州的生命科学研究和生命科学公司，并促进该区域的业务发展）的董事会任职。他获得印第安纳州的生命科学研究和生命科学公司的工商管理学士学位和工商管理硕士学位。
- William Ringo became a director in July 2014 upon the closing of the Assembly Pharmaceuticals, Inc. acquisition through a reverse merger by Assembly Biosciences, Inc. predecessor company, Ventrus Biosciences, Inc. the Merger and became non-executive Chairman of the Board in February 2015. Mr. Ringo served as Interim Chief Executive Officer of Five Prime Therapeutics, Inc. (Five Prime) from September 2019 until April 2020. From July 2010 until December 2015 Mr. Ringo was a senior advisor with Barclays Capital, the global investment banking division of Barclays Bank PLC. From July 2010 until December 2015 Mr. Ringo served as a strategic advisor with Sofinnova Ventures, a life sciences-focused investment firm. Prior to his advisory roles with Barclays Capital and Sofinnova Ventures, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer Inc., a biopharmaceutical company, from April 2008 until his retirement in April 2010. From 2004 to 2006 Mr. Ringo served as President and Chief Executive Officer of Abgenix, Inc., a biotechnology company acquired by Amgen, Inc. From 2001 to 2007 he served on various boards of directors, including the following public companies: Encysive Pharmaceuticals, Inc.; Inspire Pharmaceuticals, Inc.; and InterMune, Inc., where he was the non-executive chairman of the board of directors after serving as interim Chief Executive Officer from June 2003 to September 2003. His experience in the global pharmaceutical sector also includes nearly 30 years with Lilly. Over the course of his career with Lilly, Mr. Ringo served in numerous executive roles, including Product Group President for oncology and critical care, President of internal medicine products, President of the infectious diseases business unit, and Vice President of sales and marketing for U.S. pharmaceuticals. He also was a member of Lilly's operating committee. From 1994 to 2002 he served as a director and chairman of the board for Community Health Systems, Inc. and from February 2011 until the October 2013 acquisition by Amgen, Inc., on the Onyx Pharmaceuticals, Inc. board of directors. In the last five years, Mr. Ringo served as a director of Immune Design Corp., Sangamo Biosciences, Inc., Mirati Technologies, Inc., each public companies, and Dermira, Inc. (Dermira) prior to Dermira being acquired by Lilly and Five Prime prior to Five Prime being acquired by Amgen Inc. Prior to being acquired, both Dermira and Five Prime were also public companies. In addition, Mr. Ringo currently serves as the chairman of the board at Sensei Biotherapeutics, Inc. Mr. Ringo received a B.S. in business administration and an M.B.A. from the University of Dayton.
高管简历
中英对照 | 中文 | 英文- John G. McHutchison
John G. McHutchison于2018年3月被任命为首席科学官。在加入Gilead之前，McHutchison博士曾在杜克大学医学中心工作，并担任过杜克临床研究所副所长。 他还担任过杜克大学医学中心胃肠病学系医学教授，杜克大学临床研究所副所长和杜克大学临床与转化科学奖的联合主任。 在Duke任职之前，McHutchison博士在Scripps诊所工作了近10年，最近担任肝脏移植医学总监。 他之前还曾在南加州大学担任医学助理教授。
John G. McHutchison has served as our Chief Executive Officer and President and as a director since August 2019. Prior to joining us, Dr. McHutchison was the Chief Scientific Officer and Head of Research and Development at Gilead Sciences, Inc. Gilead. Prior to joining Gilead in 2010 Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke University, Dr. McHutchison spent nearly ten years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018 Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology. Dr. McHutchison has undergraduate degrees in medicine and surgery from the University of Melbourne in Australia and completed his residency in internal medicine and fellowship in gastroenterology at the Royal Melbourne Hospital. He is a member of the Royal Australasian College of Physicians. Dr. McHutchison currently serves on the board of directors of Metacrine, Inc., a public company, and Evox Therapeutics and Oxford BioTherapeutics, both private companies.- John G. McHutchison于2018年3月被任命为首席科学官。在加入Gilead之前，McHutchison博士曾在杜克大学医学中心工作，并担任过杜克临床研究所副所长。 他还担任过杜克大学医学中心胃肠病学系医学教授，杜克大学临床研究所副所长和杜克大学临床与转化科学奖的联合主任。 在Duke任职之前，McHutchison博士在Scripps诊所工作了近10年，最近担任肝脏移植医学总监。 他之前还曾在南加州大学担任医学助理教授。
- John G. McHutchison has served as our Chief Executive Officer and President and as a director since August 2019. Prior to joining us, Dr. McHutchison was the Chief Scientific Officer and Head of Research and Development at Gilead Sciences, Inc. Gilead. Prior to joining Gilead in 2010 Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke University, Dr. McHutchison spent nearly ten years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018 Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology. Dr. McHutchison has undergraduate degrees in medicine and surgery from the University of Melbourne in Australia and completed his residency in internal medicine and fellowship in gastroenterology at the Royal Melbourne Hospital. He is a member of the Royal Australasian College of Physicians. Dr. McHutchison currently serves on the board of directors of Metacrine, Inc., a public company, and Evox Therapeutics and Oxford BioTherapeutics, both private companies.
- Jason A. Okazaki
Jason A. Okazaki自2021年8月起担任我们的首席运营官。Okazaki先生自2020年3月起担任我们的首席法律和商务官，直到他晋升为首席运营官。在加入我们之前，Okazaki先生从2006年到2020年3月在Gilead的法律部门担任了一系列职责不断增加的职位，最终担任高级副总裁、法律和助理秘书。在吉列德期间，冈崎骏曾就战略交易、公司治理、证券交易委员会事务和运营合同提供咨询。他还领导亚洲和拉丁美洲的法律组织。在加入Gilead之前，Okazaki先生是Skadden，Arps，Slate，Meagher & Flom LLP的高级合伙人，在那里他代表公司处理合并、收购和公司财务事宜。Okazaki先生在斯坦福大学获得经济学学士学位，在加州大学黑斯廷斯法学院获得法学博士学位。
Jason A. Okazaki has served as our Chief Operating Officer since August 2021. Mr. Okazaki served as our Chief Legal and Business Officer from March 2020 until his promotion to Chief Operating Officer. Prior to joining us, Mr. Okazaki served in a series of positions of increasing responsibility in Gilead’s legal department from 2006 until March 2020 culminating in his role as Senior Vice President, Legal, and Assistant Secretary. While at Gilead, Mr. Okazaki advised on strategic transactions, corporate governance, SEC matters and operational contracts. He also led the Asia and Latin America legal organizations. Prior to joining Gilead, Mr. Okazaki was a senior associate at Skadden, Arps, Slate, Meagher & Flom LLP, where he represented companies in connection with mergers, acquisitions and corporate finance matters. Mr. Okazaki received a B.A. in Economics from Stanford University and a J.D. from U.C. Hastings College of the Law.- Jason A. Okazaki自2021年8月起担任我们的首席运营官。Okazaki先生自2020年3月起担任我们的首席法律和商务官，直到他晋升为首席运营官。在加入我们之前，Okazaki先生从2006年到2020年3月在Gilead的法律部门担任了一系列职责不断增加的职位，最终担任高级副总裁、法律和助理秘书。在吉列德期间，冈崎骏曾就战略交易、公司治理、证券交易委员会事务和运营合同提供咨询。他还领导亚洲和拉丁美洲的法律组织。在加入Gilead之前，Okazaki先生是Skadden，Arps，Slate，Meagher & Flom LLP的高级合伙人，在那里他代表公司处理合并、收购和公司财务事宜。Okazaki先生在斯坦福大学获得经济学学士学位，在加州大学黑斯廷斯法学院获得法学博士学位。
- Jason A. Okazaki has served as our Chief Operating Officer since August 2021. Mr. Okazaki served as our Chief Legal and Business Officer from March 2020 until his promotion to Chief Operating Officer. Prior to joining us, Mr. Okazaki served in a series of positions of increasing responsibility in Gilead’s legal department from 2006 until March 2020 culminating in his role as Senior Vice President, Legal, and Assistant Secretary. While at Gilead, Mr. Okazaki advised on strategic transactions, corporate governance, SEC matters and operational contracts. He also led the Asia and Latin America legal organizations. Prior to joining Gilead, Mr. Okazaki was a senior associate at Skadden, Arps, Slate, Meagher & Flom LLP, where he represented companies in connection with mergers, acquisitions and corporate finance matters. Mr. Okazaki received a B.A. in Economics from Stanford University and a J.D. from U.C. Hastings College of the Law.
- William E. Delaney IV
William E. Delaney IV自2020年5月起担任我们的首席科学官。在加入我们之前，德莱尼博士从2000年到2020年5月在吉列德的临床病毒学和生物学研究小组担任过一系列职责不断增加的职位，最终担任生物学执行董事。在加入Gilead之前，Delaney博士从1999年到2000年在维多利亚州传染病参考实验室担任研究和分子开发研究员。Delaney博士在特拉华大学获得生物技术学士学位，在宾夕法尼亚州立大学医学院获得细胞和分子生物学博士学位。
William E. Delaney IV has served as our Chief Scientific Officer since May 2020. Prior to joining us, Dr. Delaney served in a series of positions of increasing responsibility in Gilead’s clinical virology and biology research groups from 2000 until May 2020 culminating in his role as Executive Director, Biology. Prior to joining Gilead, Dr. Delaney was a research and molecular development fellow at Victorian Infectious Diseases Reference Laboratory from 1999 until 2000. Dr. Delaney received a B.S. in Biotechnology from the University of Delaware and a Ph.D. in Cell and Molecular Biology from Penn State University, College of Medicine.- William E. Delaney IV自2020年5月起担任我们的首席科学官。在加入我们之前，德莱尼博士从2000年到2020年5月在吉列德的临床病毒学和生物学研究小组担任过一系列职责不断增加的职位，最终担任生物学执行董事。在加入Gilead之前，Delaney博士从1999年到2000年在维多利亚州传染病参考实验室担任研究和分子开发研究员。Delaney博士在特拉华大学获得生物技术学士学位，在宾夕法尼亚州立大学医学院获得细胞和分子生物学博士学位。
- William E. Delaney IV has served as our Chief Scientific Officer since May 2020. Prior to joining us, Dr. Delaney served in a series of positions of increasing responsibility in Gilead’s clinical virology and biology research groups from 2000 until May 2020 culminating in his role as Executive Director, Biology. Prior to joining Gilead, Dr. Delaney was a research and molecular development fellow at Victorian Infectious Diseases Reference Laboratory from 1999 until 2000. Dr. Delaney received a B.S. in Biotechnology from the University of Delaware and a Ph.D. in Cell and Molecular Biology from Penn State University, College of Medicine.
- Luisa M. Stamm
Luisa M. Stamm自2019年11月起担任我们的首席医疗官。在加入我们之前，Stamm博士从2013年7月至2019年11月在吉利德的临床研究小组担任了一系列职责不断增加的职位，最终担任临床研究执行董事。在加入Gilead之前，Stamm博士从2013年1月至2013年7月在哈佛医学院担任讲师。从2009年到2013年7月，Stamm博士是马萨诸塞州总医院传染病的临床和研究员。Stamm博士在哈佛大学获得生物化学学士学位，在加州大学旧金山分校获得生物医学科学医学博士和博士学位。
Luisa M. Stamm has served as our Chief Medical Officer since November 2019. Prior to joining us, Dr. Stamm served in a series of positions of increasing responsibility in Gilead’s clinical research group from July 2013 until November 2019 culminating in her role as Executive Director, Clinical Research. Prior to joining Gilead, Dr. Stamm was an instructor at Harvard Medical School from January 2013 until July 2013. From 2009 until July 2013 Dr. Stamm was a clinical and research fellow in infectious disease at Massachusetts General Hospital. Dr. Stamm received a B.A. in Biochemistry from Harvard University and an M.D. and a Ph.D. in Biomedical Sciences from the University of California, San Francisco.- Luisa M. Stamm自2019年11月起担任我们的首席医疗官。在加入我们之前，Stamm博士从2013年7月至2019年11月在吉利德的临床研究小组担任了一系列职责不断增加的职位，最终担任临床研究执行董事。在加入Gilead之前，Stamm博士从2013年1月至2013年7月在哈佛医学院担任讲师。从2009年到2013年7月，Stamm博士是马萨诸塞州总医院传染病的临床和研究员。Stamm博士在哈佛大学获得生物化学学士学位，在加州大学旧金山分校获得生物医学科学医学博士和博士学位。
- Luisa M. Stamm has served as our Chief Medical Officer since November 2019. Prior to joining us, Dr. Stamm served in a series of positions of increasing responsibility in Gilead’s clinical research group from July 2013 until November 2019 culminating in her role as Executive Director, Clinical Research. Prior to joining Gilead, Dr. Stamm was an instructor at Harvard Medical School from January 2013 until July 2013. From 2009 until July 2013 Dr. Stamm was a clinical and research fellow in infectious disease at Massachusetts General Hospital. Dr. Stamm received a B.A. in Biochemistry from Harvard University and an M.D. and a Ph.D. in Biomedical Sciences from the University of California, San Francisco.
- Michael P. Samar
Michael P. Samar自2021年8月起担任我们的首席财务官。Samar先生自2019年7月起担任财务和业务运营高级副总裁，直至晋升为首席财务官。在此之前，Samar先生从2019年5月至2019年7月担任财务和业务运营副总裁，从2017年6月至2019年4月担任财务副总裁。在加入公司之前，Samar先生在Acorda Therapeutics，Inc.收购Biotie Therapies Corp.后，于2016年4月至2017年4月担任财务副总裁，他在2014年2月至2016年4月担任同一职务。Samar先生在布赖恩特大学获得金融学学士学位，在维拉诺瓦大学获得工商管理硕士学位。
Michael P. Samar has served as our Chief Financial Officer since August 2021. Mr. Samar served as Senior Vice President, Finance and Business Operations from July 2019 until his promotion to Chief Financial Officer. Prior to that, Mr. Samar served as Vice President, Finance and Business Operations from May 2019 until July 2019 and Vice President, Finance from June 2017 until April 2019. Prior to joining the Company, Mr. Samar served as Vice President of Finance at Acorda Therapeutics, Inc. from April 2016 until April 2017 following its acquisition of Biotie Therapies Corp., where he served in the same role from February 2014 until April 2016. Mr. Samar received a B.S.B.A. in Finance from Bryant University and an M.B.A. from Villanova University.- Michael P. Samar自2021年8月起担任我们的首席财务官。Samar先生自2019年7月起担任财务和业务运营高级副总裁，直至晋升为首席财务官。在此之前，Samar先生从2019年5月至2019年7月担任财务和业务运营副总裁，从2017年6月至2019年4月担任财务副总裁。在加入公司之前，Samar先生在Acorda Therapeutics，Inc.收购Biotie Therapies Corp.后，于2016年4月至2017年4月担任财务副总裁，他在2014年2月至2016年4月担任同一职务。Samar先生在布赖恩特大学获得金融学学士学位，在维拉诺瓦大学获得工商管理硕士学位。
- Michael P. Samar has served as our Chief Financial Officer since August 2021. Mr. Samar served as Senior Vice President, Finance and Business Operations from July 2019 until his promotion to Chief Financial Officer. Prior to that, Mr. Samar served as Vice President, Finance and Business Operations from May 2019 until July 2019 and Vice President, Finance from June 2017 until April 2019. Prior to joining the Company, Mr. Samar served as Vice President of Finance at Acorda Therapeutics, Inc. from April 2016 until April 2017 following its acquisition of Biotie Therapies Corp., where he served in the same role from February 2014 until April 2016. Mr. Samar received a B.S.B.A. in Finance from Bryant University and an M.B.A. from Villanova University.